Back

CS585, a novel prostacyclin receptor agonist, demonstrates sustained efficacy in vivo in the prevention of thrombosis

31 August 2024 (13:15 - 13:25)
Organised by: Logo
Congress Presentation Part of: Biotherapies in cardiovascular disease: from bench to bedside Antiplatelet Drugs ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Michael Holinstat

University of Michigan, Ann Arbor (United States of America)

5 More presentations in this session

Presentation thumbnail
RKER-012, a novel modified ActRIIB ligand trap, attenuated right ventricular cardiomyopathy in a preclinical model of pulmonary arterial hypertension.
Doctor P. Jain (Lexington, US) Doctor K. Babbs (US)
Abstract Slides Video
Presentation thumbnail
First-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RBD4059, a GalNAc-siRNA drug targeting coagulation factor XI (FXI), in healthy subjects
Doctor A. Gabrielsen (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
Preclinical characterisation and first-in-human results on the tolerability and pharmacodynamic effect of REGN9933, a monoclonal antibody targeting the factor XI/activated factor XI apple 2 domain
Doctor A. Kithcart (US)
Abstract Slides Video
Presentation thumbnail
Phase I results of both IV and oral administration for CG-0255: a novel fast-acting antiplatelet drug with a new activation pathway
Doctor X. Chen (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Developing p21-activated kinase 1 (PAK1) activators to treat hypertrophic cardiomyopathy (HCM)
Miss Y. He (Oxford, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Biotherapies in cardiovascular disease: from bench to bedside
Video

The Event

Event poster

ESC Congress 2024

31 August 2024 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Superiority of CS585 as a selective prostacyclin receptor agonist in prevention of thrombosis
thumbnail
Congress Session
Biotherapies in cardiovascular disease: from bench to bedside
thumbnail
Congress Presentation
Phase I results of both IV and oral administration for CG-0255: a novel fast-acting antiplatelet drug with a new activation pathway

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources